The synthetic, investigational, peptide-based erythropoiesis-stimulating agent peginesatide can increase hemoglobin level in patients with chronic kidney disease who are not on dialysis, say researchers. Macdougall et al. treated 139 patients with peginesatide in 10 different cohorts (differing in dose, frequency and route of administration). Administering peginesatide every 4 weeks increased and maintained hemoglobin levels.
ORIGINAL RESEARCH PAPER
Macdougall, I. C. et al. Dose–finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. doi:10.2215/CJN.10831210
Rights and permissions
About this article
Cite this article
Peginesatide for correction of renal anemia. Nat Rev Nephrol 7, 676 (2011). https://doi.org/10.1038/nrneph.2011.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.159